| Literature DB >> 28321777 |
Júlia Teixeira de Oliveira1,2, Maria C da Silva Barbosa1,2, Luiz F de Camargos1,2, Isabella Viana Gomes da Silva1, Fernando de Pilla Varotti2, Luciana M da Silva3, Leonardo Marmo Moreira4, Juliana Pereira Lyon5, Vanessa J da Silva Vieira Dos Santos1, Fabio Vieira Dos Santos6,7.
Abstract
Digoxin is a drug widely used to treat heart failure and studies have demonstrated its potential as anticancer agent. In addition, digoxin presents the potential to interact with a series of other compounds used in medicine. The aim of the present study was to evaluate in vitro the cytotoxicity, genotoxicity and mutagenicity of digoxin and its potential to interact with the mutagen Mitomycin C (MMC). The cytotoxicity of digoxin was assessed by employing the MTT method and the comet assay was performed to assess the genotoxicity of this medicine in CHO-K1 and HeLa cell lines. Besides, the cytokinesis-block micronucleus assay was performed to assess the mutagenicity and the antimutagenicity of this drug. The Ames assay was also performed with TA98 and TA100 strains of S. typhimurium. Results showed that digoxin was cytotoxic, genotoxic and mutagenic for HeLa and CHO-K1 cell lines at concentrations many times higher than those observed in human therapeutic conditions. Nevertheless, an antimutagenic effect against the mutagen MMC was observed on both cell lines in concentrations near those used therapeutically in humans. This chemoprotective effect observed is an interesting finding that should be better explored regarding its impact in anticancer chemotherapy.Entities:
Keywords: Antimutagenicity; Desmutagen; Genotoxicity; Mutagenicity
Year: 2017 PMID： 28321777 PMCID： PMC5507848 DOI： 10.1007/s10616-017-0078-3
Source DB: PubMed Journal: Cytotechnology ISSN： 0920-9069 Impact factor: 2.058